NAS:GLPG (Belgium) Also trade in: Austria Belgium Germany Netherlands UK

Galapagos NV

$ 119.15 1.09 (0.92%)
Volume: 11,972 Avg Vol (1m): 123,126
Market Cap $: 6.42 Bil Enterprise Value $: 5.05 Bil
P/E (TTM): 0.00 P/B: 4.96
Earnings Power Value -7.69
Net Current Asset Value 21.05
Tangible Book 23.78
Projected FCF 10.34
Median P/S Value 152.96
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
90.35% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
GLPG: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 2.96, Med: 2839.12, Max: 127912.33
Current: 10000
2.96
127912.33
Equity-to-Asset 0.84
Equity-to-Asset ranked higher than
58.32% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
GLPG: 0.84
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.68, Med: 0.77, Max: 0.91
Current: 0.84
0.68
0.91
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 15.51
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 9.97%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -23.25
Operating Margin ranked higher than
54.42% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
GLPG: -23.25
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -226.09, Med: -18.6, Max: 2.08
Current: -23.25
-226.09
2.08
Net Margin % -14.31
Net Margin ranked higher than
53.41% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
GLPG: -14.31
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -299.3, Med: -7.17, Max: 47.88
Current: -14.31
-299.3
47.88
ROE % -3.79
ROE ranked higher than
70.78% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
GLPG: -3.79
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -41.46, Med: -3.73, Max: 17.79
Current: -3.79
-41.46
17.79
ROA % -3.01
ROA ranked higher than
72.05% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
GLPG: -3.01
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -33.22, Med: -2.52, Max: 11.91
Current: -3.01
-33.22
11.91
ROC (Joel Greenblatt) % -131.90
ROC (Joel Greenblatt) ranked higher than
53.09% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
GLPG: -131.9
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1001.82, Med: -93.51, Max: 389.23
Current: -131.9
-1001.82
389.23
3-Year Total Revenue Growth Rate 94.00
3-Year Revenue Growth Rate ranked higher than
54.38% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
GLPG: 71
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -40, Med: 4.9, Max: 71
Current: 71
-40
71
3-Year Total EBITDA Growth Rate 37.50
3-Year EBITDA Growth Rate ranked lower than
79.55% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
GLPG: 44.8
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -70.45, Max: 45.7
Current: 44.8
0
45.7
3-Year EPS w/o NRI Growth Rate 44.70
3-Year EPS w/o NRI Growth Rate ranked lower than
78.37% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
GLPG: 44.7
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -22.25, Max: 69.5
Current: 44.7
0
69.5

» GLPG's 30-Y Financials

Financials (Next Earnings Date: 2019-07-25)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:GLPG

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 0    SIC : 0
Compare NAS:EXEL NAS:AMRN SZSE:002007 TSE:4587 NAS:NKTR NAS:ASND BOM:532523 SZSE:002252 NAS:NBIX HKSE:06160 NAS:ARRY SZSE:300347 NAS:TECH NAS:JAZZ NAS:ALKS XBRU:ARGX HKSE:01530 SZSE:000661 HKSE:01548 NAS:BLUE
Traded in other countries GXE.Germany 0JXZ.UK
Address Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Ratios

Current vs industry vs history
PB Ratio 4.96
PB Ratio ranked lower than
60.40% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
GLPG: 4.96
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.03, Med: 4.05, Max: 6.18
Current: 4.96
2.03
6.18
PS Ratio 19.96
PS Ratio ranked lower than
76.45% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
GLPG: 19.96
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 12.29, Med: 25.89, Max: 57.81
Current: 19.96
12.29
57.81
EV-to-EBIT -138.10
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
GLPG: -138.1
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -298.2, Med: -26.4, Max: 609.3
Current: -138.1
-298.2
609.3
EV-to-EBITDA -143.00
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
GLPG: -143
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -385.1, Med: -27.8, Max: 370.2
Current: -143
-385.1
370.2
EV-to-Revenue 16.11
EV-to-Revenue ranked lower than
65.11% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
GLPG: 16.11
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 6.6, Med: 22.3, Max: 48.4
Current: 16.11
6.6
48.4
Current Ratio 6.31
Current Ratio ranked higher than
50.47% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
GLPG: 6.31
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.16, Med: 3.54, Max: 10.67
Current: 6.31
1.16
10.67
Quick Ratio 6.31
Quick Ratio ranked higher than
53.07% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
GLPG: 6.31
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.15, Med: 3.53, Max: 10.66
Current: 6.31
1.15
10.66
Days Inventory 0.30
Days Inventory ranked higher than
99.58% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
GLPG: 0.3
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 0.3, Med: 0.86, Max: 11.56
Current: 0.3
0.3
11.56
Days Sales Outstanding 19.73
Days Sales Outstanding ranked higher than
54.04% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
GLPG: 19.73
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 7.05, Med: 63.44, Max: 163.7
Current: 19.73
7.05
163.7
Days Payable 75.84
Days Payable ranked higher than
68.66% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
GLPG: 75.84
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 52.6, Med: 77.82, Max: 107.85
Current: 75.84
52.6
107.85

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -10.10
3-Year Share Buyback Rate ranked lower than
60.21% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
GLPG: -10.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -51.6, Med: -9.25, Max: -2.2
Current: -10.1
-51.6
-2.2

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.96
Price-to-Tangible-Book ranked lower than
51.57% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
GLPG: 4.96
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.89, Med: 3.73, Max: 6.2
Current: 4.96
1.89
6.2
Price-to-Projected-FCF 11.42
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
75.65% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
GLPG: 11.42
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 3.53, Med: 6.85, Max: 113.41
Current: 11.42
3.53
113.41
Price-to-Median-PS-Value 0.77
Price-to-Median-PS-Value ranked lower than
81.27% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
GLPG: 0.77
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.53, Med: 0.94, Max: 1.92
Current: 0.77
0.53
1.92
Earnings Yield (Joel Greenblatt) % -0.73
Earnings Yield (Greenblatt) ranked higher than
69.94% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
GLPG: -0.73
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -11.9, Med: -3.25, Max: 3.6
Current: -0.73
-11.9
3.6

More Statistics

Revenue (TTM) (Mil) $ 327.1
EPS (TTM) $ -0.83
Beta 1.41
Volatility % 40.27
52-Week Range $ 85 - 125.48
Shares Outstanding (Mil) 54.61

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y